PARP Inhibitor Staves Off Recurrence in Early BRCA-Mutant Breast Cancer
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival in patients with early, high-risk HER2-negative breast cancer and germline BRCA mutations, according to results from a phase III study reported at the virtual ...
from Google Alert - Business https://ift.tt/3gtSOL5
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival in patients with early, high-risk HER2-negative breast cancer and germline BRCA mutations, according to results from a phase III study reported at the virtual ... https://ift.tt/eA8V8J
from Google Alert - Business https://ift.tt/3gtSOL5
The addition of olaparib (Lynparza) to standard treatment significantly improved disease-free survival in patients with early, high-risk HER2-negative breast cancer and germline BRCA mutations, according to results from a phase III study reported at the virtual ... https://ift.tt/eA8V8J
Comments
Post a Comment